- Home
- Products
Qinlock (Ripretinib)
Qinlock (Ripretinib)
- Medicine Name: Qinlock
- Generic Name: Ripretinib
- Dosage Form & Strength: Tablets – 50 mg
- Manufactured By: Deciphera Pharmaceuticals
- FDA Approval Date: May 15, 2020
Qinlock is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have previously received treatment with three or more kinase inhibitors, including imatinib.
Recommended Dosage:
- 150 mg orally once daily, with or without food
- Tablets must be swallowed whole
- If a dose is missed and less than 8 hours have passed, the missed dose may be taken
- Continue treatment until disease progression or unacceptable toxicity
Hypertension: Do not initiate therapy in patients with uncontrolled high blood pressure. Monitor and manage blood pressure during treatment
Cardiac Function: Assess ejection fraction before and during treatment. Discontinue permanently if Grade 3/4 left ventricular dysfunction occurs
Wound Healing Complications: Ripretinib may impair wound healing. Monitor surgical patients closely
Fetal Risk: Ripretinib may cause fetal harm. Avoid use in pregnancy and advise contraception during treatment
Documents Required for Import to India:
- Valid prescription from a licensed oncologist
- Patient’s diagnostic reports
- Government-issued ID proof
- Import permit, if applicable
Availability:
Qinlock is not available in retail pharmacies in India but can be legally imported under Named Patient Authorization. Delivery is possible in cities like Mumbai, Delhi, Hyderabad, Bangalore, Pune, Kolkata, Chennai, Ahmedabad, and across India.
Global Rare Meds sources QINLOCK (Ripretinib) from trusted global partners in the USA, Canada, Europe, and Australia.
- Dispatched from our licensed fulfillment center in Ambernath, Thane District
- Verified and dispensed by registered pharmacists
- Global delivery with full documentation and compliance
What is the generic name of Qinlock?
Ripretinib
Who manufactures Qinlock?
Deciphera Pharmaceuticals
Is Qinlock FDA approved?
Yes, Qinlock was approved by the FDA on May 15, 2020
What condition does Qinlock treat?
Advanced gastrointestinal stromal tumor (GIST) after three or more previous kinase inhibitor therapies
What is the dosage and form?
Tablets – 50 mg, administered orally
What are the most common side effects?
Vomiting, nausea, alopecia, abdominal pain, diarrhea, constipation, fatigue, decreased appetite, muscle pain, and hand-foot syndrome
What are the storage conditions?
Store at 20°C to 25°C (68°F to 77°F). Keep in the original container with desiccant packet. Do not remove desiccant.
Is Qinlock available in India?
Yes, via named patient import. Not commercially available in Indian pharmacies.
How much does Qinlock cost in India?
Contact Global Rare Meds for current pricing:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
